Northwestern cured mouse Lyme with an approved drug at 1/100th the dose

Lyme disease, spread by deer-tick bites, responds to early antibiotics, but the gold standard doxycycline is a blunt instrument: it kills beneficial gut bacteria alongside Borrelia burgdorferi, fails between 10% and 20% of patients, and is not approved for young children, the group at highest risk of tick bites. With roughly half a million Americans diagnosed and treated each year and climate change lengthening tick seasons, a more targeted option was needed.

Rather than hunt for a new molecule, Jutras's Northwestern team screened nearly 500 medicines in a drug library, scoring each antibiotic's likely interaction with the Lyme bacterium through a molecular framework, then physiological, cellular and molecular tests. The screen surfaced piperacillin, an antibiotic FDA-approved for pneumonia, which interferes exclusively with the unusual cell-wall synthesis pattern common to Lyme bacteria, blocking growth and division. It cured mice at a dose 100 times smaller than doxycycline's effective dose, with virtually no impact on resident gut microbes.

The second study attacked the puzzle of lingering illness, which a 2022 Johns Hopkins study found affects 14% of even early-treated patients. By tracking peptidoglycan, the cell-wall remnant antibiotics act on, the team showed Borrelia's version is chemically distinct, persists for weeks to months, and ends up in the liver, which cannot process it; the body's response to that debris, not a live infection, may drive chronic symptoms. That reframes therapy from sterilizing a possibly gone infection toward neutralizing the inflammatory molecule.

Hit the bug's one unique weakness with an approved drug

The molecular framework ranked candidates by mechanism, so hundreds of drugs could be triaged without blind efficacy trials.

Repurposing an FDA-approved drug skips years of safety work and makes preventive use after a known tick bite plausible.

Hitting a pathway unique to Borrelia let the dose fall 100x, which is what spared the gut microbiome.

Explaining PTLD as persistent peptidoglycan redirects treatment at the immune trigger and mirrors the leading theory of long COVID.

Find what is unique about the target, screen already-approved tools against it, and the effective dose and collateral damage can both collapse.

Both studies appeared in Science Translational Medicine in April 2025. The piperacillin result is in mice — no human Lyme trial is reported and the drug is not approved for this use — while the peptidoglycan work points toward more accurate tests for Post Treatment Lyme Disease and treatments that neutralize the inflammatory molecule rather than re-treating an infection that may no longer exist. Jutras describes the aim as customized combinations for patients who fail standard therapy; no approved human Lyme vaccine exists.